Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 366 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Transplant Patients Clear all
Completed Not applicable Interventional

Increasing Communication About Live Donor Kidney Transplant

NCT01855438
View directory record Official record
Conditions
Kidney Transplant Candidates
Interventions
Living Donor Transplant Education
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 10, 2026, 6:47 PM EDT
Terminated Phase 4 Interventional Results available

A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms

NCT00658333
View directory record Official record
Conditions
Renal Transplantation
Interventions
Enteric-coated Mycophenolate Acid (EC-MPA), Mycophenolate Mofetil (MMF), Placebo MMF, Placebo EC-MPA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Not applicable Interventional

iChoose Decision Kidney Aid for End-Stage Renal Disease Patients

NCT02235571
View directory record Official record
Conditions
End-Stage Kidney Disease, Kidney Failure, Chronic, Kidney Transplantation
Interventions
iChoose Kidney Decision Aid
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 10, 2026, 6:47 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dental Intervention Plan for Chronic Kidney Disease Patients Awaiting or With Kidney Transplant

NCT04020458
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Periodontitis, Generalized, Moderate
Interventions
dental intervention
Procedure
Lead sponsor
Augusta University
Other
Eligibility
21 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Not applicable Interventional

Video Education and Behaviour Contract to Optimize Adherence in Renal Transplants

NCT03540121
View directory record Official record
Conditions
Kidney Transplantation, Medication Adherence
Interventions
Video education + adherence contract
Behavioral
Lead sponsor
University of Saskatchewan
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 10, 2026, 6:47 PM EDT
Completed No phase listed Observational

Studies of Organ Transplantation in Animals and Man

NCT00156364
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Michael Mauer, MD
Individual
Eligibility
18 Years to 60 Years
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1981 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Phase 2 Interventional Results available

Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient

NCT00263328
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Phase 3 Interventional Results available

Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

NCT02118896
View directory record Official record
Conditions
Heart Transplantation, Liver Transplantation, Kidney Transplantation
Interventions
FK506E
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 10, 2026, 6:47 PM EDT
Withdrawn Phase 2 Interventional

Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)

NCT00878761
View directory record Official record
Conditions
Chronic Allograft Dysfunction
Interventions
STX-100
Biological
Lead sponsor
Stromedix, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Oct 10, 2026, 6:47 PM EDT
Terminated No phase listed Observational

CEC/EPC and Cardiovascular Risk in Renal Transplant Recipients

NCT00365833
View directory record Official record
Conditions
Transplantation, Kidney, Cardiovascular Abnormalities, Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2011 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

NCT01178216
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Rituxan
Biological
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 10, 2026, 6:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients

NCT00767897
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis
Interventions
Human Papillomavirus Vaccine
Drug
Lead sponsor
Indiana University
Other
Eligibility
9 Years to 18 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Phase 1Phase 2 Interventional

YSPSL for Prevention of Delayed Graft Function Part B

NCT00298168
View directory record Official record
Conditions
Kidney Diseases
Interventions
YSPSL, placebo
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 10, 2026, 6:47 PM EDT
Recruiting No phase listed Observational

The KidneyCARE (Community Access to Research Equity) Study

NCT05497518
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis, Kidney Transplant
Interventions
Observational study - registry
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2070
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 10, 2026, 6:47 PM EDT
Withdrawn Phase 4 Interventional

The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone

NCT02030314
View directory record Official record
Conditions
Resistant Hypertension in Kidney Transplant Patients
Interventions
Chlorthalidone
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Phase 4 Interventional Results available

Belatacept 3 Month Post Transplant Conversion Study

NCT02213068
View directory record Official record
Conditions
Transplant; Failure, Kidney, EBV
Interventions
belatacept, Tacrolimus, MPA
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 10, 2026, 6:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

NCT06625190
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft Part Sarcoma, Desmoplastic Small Round Cell Tumor, Chordoma, Rhabdoid Tumor, Epithelioid Sarcoma, Myoepithelial Tumor, Osteosarcoma, Ewing Sarcoma, Wilms Tumor
Interventions
Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
Device · Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Months to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation

NCT02123108
View directory record Official record
Conditions
Liver Transplantation
Interventions
Basiliximab, Tacrolimus, Mycophenolic Acid
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Phase 4 Interventional

A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients

NCT00650468
View directory record Official record
Conditions
Renal Transplantation
Interventions
tacrolimus, CellCept, steroids (methylprednisone or prednisone)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
29
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 10, 2026, 6:47 PM EDT
Completed No phase listed Observational

Assessment of Renal Function in Cirrhotic Patients

NCT01895114
View directory record Official record
Conditions
Liver Failure, Renal Failure
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Not applicable Interventional

Communicating About Choices in Transplantation

NCT01853007
View directory record Official record
Conditions
End Stage Renal Disease and Kidney Transplantation
Interventions
COACH Program
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Early Phase 1 Interventional

Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant

NCT02687763
View directory record Official record
Conditions
RENAL INSUFFICIENCY, CHRONIC, LIVER FAILURE, ACUTE, HEART DISEASE
Interventions
ProQuad
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
6 Months to 24 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Trial to Prevent New Onset Diabetes After Transplantation

NCT01683331
View directory record Official record
Conditions
Prevention of New Onset Diabetes Among Kidney Transplant Patients
Interventions
Insulin treatment for hyperglycemia
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 10, 2026, 6:47 PM EDT
Completed Phase 2 Interventional

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

NCT00002673
View directory record Official record
Conditions
Cancer
Interventions
infection prophylaxis and management
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 10, 2026, 6:47 PM EDT